Literature DB >> 25554519

Tutorial: strategies addressing detection bias were reviewed and implemented for investigating the statins-diabetes association.

Andrea Arfè1, Giovanni Corrao2.   

Abstract

OBJECTIVES: Literature on specific analytic methods for addressing detection bias is fragmented. We illustrate some analytic strategies to account for detection bias. STUDY DESIGN AND
SETTING: Several tools addressing detection bias are described, namely (1) sensitivity analysis, (2) conditioning on outcome detectability, and (3) use of negative controls. These tools are applied in a population-based cohort study on the association between adherence to statins and start of antidiabetic therapy (as proxy of type 2 diabetes mellitus onset).
RESULTS: Compared with patients on very low adherence to statins, those with high adherence had hazard ratio (HR) for diabetes of 1.53 (95% confidence interval: 1.44, 1.64). The observed association was potentially affected by detection bias because long-term exposure to statins implies a more regular use of primary care services, triggering the search for diabetes. Nevertheless, from the considered tools, (1) we showed that the HR for diabetes risk decreased to 1.28 if diabetes detection was assumed to be 20% more likely in highly adherent patients; (2) an increased risk of diabetes was found among patients with no specialist visits during the first year of follow-up; (3) no association was found between adherence to bisphosphonates (negative exposure) and diabetes nor between adherence to statins and initiation of antihypertensive pharmacotherapy (negative outcome).
CONCLUSION: Implementation of analytic strategies for addressing detection bias is advisable whenever this is suspected. As illustrated, several methods could be considered. Their implementation suggested that detection bias had a limited impact in our application.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Detection bias; Healthcare utilization database; Negative controls; Observational studies; Outcome detectability; Sensitivity analysis; Statins; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2014        PMID: 25554519     DOI: 10.1016/j.jclinepi.2014.12.001

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  7 in total

1.  Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors.

Authors:  Heidi S Wirtz; Gregory S Calip; Diana S M Buist; Julie R Gralow; William E Barlow; Shelly Gray; Denise M Boudreau
Journal:  Am J Epidemiol       Date:  2017-04-15       Impact factor: 4.897

2.  Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma.

Authors:  Jason N Barreto; Carrie A Thompson; Patrick M Wieruszewski; Amanda G Pawlenty; Kristin C Mara; Ashley L Potter; Pritish K Tosh; Andrew H Limper
Journal:  Leuk Lymphoma       Date:  2020-07-05

3.  A Latent Disease Model to Reduce Detection Bias in Cancer Risk Prediction Studies.

Authors:  Serge Aleshin-Guendel; Jane Lange; Phyllis Goodman; Noel S Weiss; Ruth Etzioni
Journal:  Eval Health Prof       Date:  2021-01-28       Impact factor: 2.651

4.  On the Nature of Informative Presence Bias in Analyses of Electronic Health Records.

Authors:  Glen McGee; Sebastien Haneuse; Brent A Coull; Marc G Weisskopf; Ran S Rotem
Journal:  Epidemiology       Date:  2022-01-01       Impact factor: 4.822

5.  Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study.

Authors:  Stefano Ciardullo; Federico Rea; Laura Savaré; Gabriella Morabito; Gianluca Perseghin; Giovanni Corrao
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

6.  Perils of Observational Data Analyses.

Authors:  Jennifer G Robinson
Journal:  J Am Heart Assoc       Date:  2019-04-16       Impact factor: 5.501

7.  The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database.

Authors:  Catherine B Johannes; Catherine W Saltus; James A Kaye; Brian Calingaert; Sigal Kaplan; Mark Forrest Gordon; Elizabeth B Andrews
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-04-06       Impact factor: 2.732

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.